Solid Biosciences Inc. (SLDB)Healthcare | Biotechnology | Charlestown, United States | NasdaqGS
9.77 USD
-0.36
(-3.554%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 9.77 |
Hot Take ↕ | Aug. 22, 2026, 3:29 a.m. EDT
This biotech stock presents a classic 'value trap' scenario where the balance sheet looks pristine but the business fundamentals are in freefall. While the company holds a fortress-like cash position relative to its debt, the operational reality is stark: it is burning massive amounts of cash with negative free cash flow and no earnings in sight. The most damning indicator is the price history; the stock has lost nearly 99% of its value over the last seven years, reflecting a market that has repeatedly rejected its growth narrative. Although there was a brief resurgence in 2024, the trend has reversed sharply, leaving the stock trading near multi-year lows. Analysts are optimistic with a high price target, but this optimism ignores the structural deterioration evident in the price action. With no dividend to provide income and a statistical forecast showing almost zero expected movement, the only logical play here is waiting for a catalyst that can reverse the decade-long decline. Until then, the risk-reward profile remains heavily skewed against the buyer. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.254634 |
| AutoETS | 0.255672 |
| AutoARIMA | 0.255678 |
| MSTL | 0.264792 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.820 |
| Excess Kurtosis | -0.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.388 |
| Market Cap | 1,047,590,656 |
| Forward P/E | -5.59 |
| Beta | 2.42 |
| Website | https://www.solidbio.com |
As of Aug. 22, 2026, 3:29 a.m. EDT: Options activity shows a distinct lack of speculative positioning. Call volume and open interest are negligible across all expirations, with no significant strikes identified for bullish bets. Put activity is similarly sparse, dominated by low-volume, deep out-of-the-money contracts rather than protective hedges or bearish bets at key levels. The implied volatility surface is flat and low, indicating a market devoid of directional conviction or fear regarding imminent price moves.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8655617 |
| Address1 | 500 Rutherford Avenue |
| Address2 | Third Floor |
| All Time High | 822.6 |
| All Time Low | 1.81 |
| Ask | 12.51 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 905,930 |
| Average Daily Volume3 Month | 1,623,680 |
| Average Volume | 1,623,680 |
| Average Volume10Days | 905,930 |
| Beta | 2.422 |
| Bid | 9.83 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 3.558 |
| City | Charlestown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.77 |
| Current Ratio | 13.823 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 10.095 |
| Day Low | 9.72 |
| Debt To Equity | 5.388 |
| Display Name | Solid Biosciences |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | -210,524,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.278 |
| Enterprise Value | 690,067,584 |
| Eps Current Year | -1.76007 |
| Eps Forward | -1.74644 |
| Eps Trailing Twelve Months | -1.82 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.1173 |
| Fifty Day Average Change | 0.6527004 |
| Fifty Day Average Change Percent | 0.071589224 |
| Fifty Two Week Change Percent | 86.556175 |
| Fifty Two Week High | 11.45 |
| Fifty Two Week High Change | -1.6799994 |
| Fifty Two Week High Change Percent | -0.14672484 |
| Fifty Two Week Low | 3.79 |
| Fifty Two Week Low Change | 5.9800005 |
| Fifty Two Week Low Change Percent | 1.5778365 |
| Fifty Two Week Range | 3.79 - 11.45 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,516,977,000,000 |
| Float Shares | 64,812,295 |
| Forward Eps | -1.74644 |
| Forward P E | -5.5942373 |
| Free Cashflow | -118,235,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 121 |
| Fullday Change | -0.36 |
| Fullday Change Percent | -3.5538 |
| Fullday Price | 9.77 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00676 |
| Held Percent Institutions | 1.0728 |
| Implied Shares Outstanding | 107,225,238 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,666,915,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. |
| Long Name | Solid Biosciences Inc. |
| Market | us_market |
| Market Cap | 1,047,590,656 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_315986912 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -207,099,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,086,191,660 |
| Number Of Analyst Opinions | 12 |
| Open | 10.02 |
| Operating Cashflow | -186,844,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 337 4680 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 9.77 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 10.13 |
| Price Eps Current Year | -5.5509157 |
| Price Hint | 2 |
| Price To Book | 2.7459247 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.213 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.30769 |
| Region | US |
| Regular Market Change | -0.36 |
| Regular Market Change Percent | -3.5538 |
| Regular Market Day High | 10.095 |
| Regular Market Day Low | 9.72 |
| Regular Market Day Range | 9.72 - 10.095 |
| Regular Market Open | 10.02 |
| Regular Market Previous Close | 10.13 |
| Regular Market Price | 9.77 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 621,510 |
| Return On Assets | -0.36383998 |
| Return On Equity | -0.655 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 107,225,238 |
| Shares Percent Shares Out | 0.155 |
| Shares Short | 16,619,915 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 17,667,300 |
| Short Name | Solid Biosciences Inc. |
| Short Percent Of Float | 0.1762 |
| Short Ratio | 17.18 |
| Source Interval | 15 |
| State | MA |
| Symbol | SLDB |
| Target High Price | 26.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 18.66667 |
| Target Median Price | 18.5 |
| Total Cash | 377,678,016 |
| Total Cash Per Share | 3.522 |
| Total Debt | 20,155,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.82 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.1429 |
| Two Hundred Day Average Change | 2.6271005 |
| Two Hundred Day Average Change Percent | 0.36779186 |
| Type Disp | Equity |
| Volume | 621,510 |
| Website | https://www.solidbio.com |
| Zip | 2,129 |